参考文献:1.Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95.PubMed CrossRef 2.Ponnuswamy P, Van Vré EA, Mallat Z, Tedgui A. Humoral and cellular immune responses in atherosclerosis: spotlight on B- and T-cells. Vascul Pharmacol. 2012;56:193–203.PubMed CrossRef 3.Guasti L, Dentali F, Castiglioni L, Maroni L, Marino F, Squizzato A, et al. Neutrophils and clinical outcomes in patients with acute coronary syndromes and/or cardiac revascularisation. A systematic review on more than 34,000 subjects. Thromb Haemost. 2011;106:591–9.PubMed CrossRef 4.Congiu T, Schembri L, Tozzi M, Guasti L, Maio RC, Cosentino M, et al. Scanning electron microscopy examination of endothelium morphology in human carotid plaques. Micron. 2010;41:532–6.PubMed CrossRef 5.Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol. 1989;135:169–75.PubMed PubMedCentral 6.Daugherty A, Rateri DL. T lymphocytes in atherosclerosis: the yin-yang of Th1 and Th2 influence on lesion formation. Circ Res. 2002;90:1039–40.PubMed CrossRef 7.Taleb S, Tedgui A, Mallat Z. Adaptive T cell immune responses and atherogenesis. Curr Opin Pharmacol. 2010;10:197–202.PubMed CrossRef 8.Mallat Z, Gojova A, Brun V, Esposito B, Fournier N, Cottrez F, et al. Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein e–knockout mice. Circulation. 2003;108:1232–7.PubMed CrossRef 9.Mor A, Planer D, Luboshits G, Afek A, Metzger S, Chajek-Shaul T, et al. Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:893–900.PubMed CrossRef 10.Heller EA, Liu E, Tager AM, Yuan Q, Lin AY, Ahluwalia N, et al. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation. 2006;113:2301–12.PubMed CrossRef 11.Maganto-García E, Bu DX, Tarrio ML, Alcaide P, Newton G, Griffin GK, et al. Foxp3 + −inducible regulatory T cells suppress endothelial activation and leukocyte recruitment. J Immunol. 2011;187:3521–9.PubMed PubMedCentral CrossRef 12.Chistiakov DA, Sobenin IA, Orekhov AN. Regulatory T cells in atherosclerosis and strategies to induce the endogenous atheroprotective immune response. Immunol Lett. 2013;151:10–22.PubMed CrossRef 13.Marino F, Guasti L, Cosentino M, Rasini E, Ferrari M, Maio RC, et al. Simvastatin treatment in subjects at high cardiovascular risk modulates AT1R expression on circulating monocytes and T lymphocytes. J Hypertens. 2008;26:1147–55.PubMed CrossRef 14.Marino F, Guasti L, Cosentino M, Ferrari M, Rasini E, Maio RC, et al. Angiotensin II type 1 receptor expression in polymorphonuclear leukocytes from high-risk subjects: changes after treatment with simvastatin. J Cardiovasc Pharmacol. 2007;49:299–305.PubMed CrossRef 15.Marino F, Maresca AM, Cosentino M, Castiglioni L, Rasini E, Mongiardi C, et al. Angiotensin II type 1 and type 2 receptor expression in circulating monocytes of diabetic and hypercholesterolemic patients over 3-month rosuvastatin treatment. Cardiovasc Diabetol. 2012;11:153.PubMed PubMedCentral CrossRef 16.Li M, Wang X, Fu W, He S, Li D, Ke Q. CD4 + CD25 + Foxp3+ regulatory T cells protect endothelial function impaired by oxidized low density lipoprotein via the KLF-2 transcription factor. Cell Physiol Biochem. 2011;28:639–48.PubMed CrossRef 17.Bu DX, Griffin G, Lichtman AH. Mechanisms for the anti-inflammatory effects of statins. Curr Opin Lipidol. 2011;22:165–70.PubMed CrossRef 18.Guasti L, Marino F, Cosentino M, Maroni L, Maresca AM, Colombo F, et al. Cytokine production from peripheral blood mononuclear cells and polymorphonuclear leukocytes in patients studied for suspected obstructive sleep apnea. Sleep Breath. 2011;15:3–11.PubMed CrossRef 19.Dentali F, Gianni M, Squizzato A, Ageno W, Castiglioni L, Maroni L, et al. Use of statins and recurrence of atrial fibrillation after catheter ablation or electrical cardioversion. A systematic review and meta-analysis. Thromb Haemost. 2011;106:363–70.PubMed CrossRef 20.National Cholesterol Education Program. Expert Panel on Detection Evaluation Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497. 21.Marino F, Guasti L, Tozzi M, Schembri L, Castiglioni L, Molteni E, et al. Gene expression of adhesion molecules in endothelial cells from patients with peripheral arterial disease is reduced after surgical revascularization and pharmacological treatment. Int J Vasc Med. 2013;2013:412761.PubMed PubMedCentral 22.Cosentino M, Fietta AM, Ferrari M, Rasini E, Bombelli R, Carcano E, et al. Human CD4 + CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. Blood. 2007;109:632–42.PubMed CrossRef 23.Sakaguchi S, Sakaguchi N. Regulatory T cells in immunologic self-tolerance and autoimmune disease. Int Rev Immunol. 2005;24:211–26.PubMed CrossRef 24.Mor A, Luboshits G, Planer D, Keren G, George J. Altered status of CD4 + CD25+ regulatory T cells in patients with acute coronary syndromes. Eur Heart J. 2006;27:2530–7.PubMed CrossRef 25.Zhao Z, Wu Y, Cheng M, Ji Y, Yang X, Liu P, et al. Activation of Th17/Th1 and Th1, but not Th17, is associated with the acute cardiac event in patients with acute coronary syndrome. Atherosclerosis. 2011;217:518–24.PubMed CrossRef 26.George J, Schwartzenberg S, Medvedovsky D, Jonas M, Charach G, Afek A, et al. Regulatory T cells and IL-10 levels are reduced in patients with vulnerable coronary plaques. Atherosclerosis. 2012;222:519–23.PubMed CrossRef 27.Han SF, Liu P, Zhang W, Bu L, Shen M, Li H, et al. The opposite-direction modulation of CD4 + CD25+ Tregs and T helper 1 cells in acute coronary syndromes. Clin Immunol. 2007;124:90–7.PubMed CrossRef 28.Hu Z, Li D, Hu Y, Yang K. Changes of CD4 + CD25+ regulatory T cells in patients with acute coronary syndrome and the effects of atorvastatin. J Huazhong Univ Sci Technolog Med Sci. 2007;27:524–7.PubMed CrossRef 29.Li Q, Wang Y, Yu F, Wang YM, Zhang C, Hu C, et al. Peripheral Th17/Treg imbalance in patients with atherosclerotic cerebral infarction. Int J Clin Exp Pathol. 2013;6:1015–27.PubMed PubMedCentral 30.Wigren M, Björkbacka H, Andersson L, Ljungcrantz I, Fredrikson GN, Persson M, et al. Low levels of circulating CD4 + FoxP3+ T cells are associated with an increased risk for development of myocardial infarction but not for stroke. Arterioscler Thromb Vasc Biol. 2012;32:2000–4.PubMed CrossRef 31.Liu ZD, Wang L, Lu FH, Pan H, Zhao YX, Wang SJ, et al. Increased Th17 cell frequency concomitant with decreased Foxp3+ Treg cell frequency were found in the peripheral circulation of patients with carotid artery plaques. Inflamm Res. 2012;61:1155–65.PubMed CrossRef 32.Ammirati E, Cianflone D, Banfi M, Vecchio V, Palini A, De Metrio M, et al. Circulating CD4 + CD25hiCD127lo regulatory T-Cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30:1832–41.PubMed CrossRef 33.Maganto-García E, Tarrio ML, Grabie N, Bu DX, Lichtman AH. Dynamic changes in regulatory T cells are linked to levels of diet-induced hypercholesterolemia. Circulation. 2011;124:185–95.PubMed PubMedCentral CrossRef 34.Bettini ML, Pan F, Bettini M, Finkelstein D, Rehg JE, Floess S, et al. Loss of epigenetic modification driven by the Foxp3 transcription factor leads to regulatory T cell insufficiency. Immunity. 2012;36:717–30.PubMed PubMedCentral CrossRef 35.Bonelli M, Savitskaya A, Steiner CW, Rath E, Smolen JS, Scheinecker C. Phenotypic and functional analysis of CD4+ CD25- Foxp3+ T cells in patients with systemic lupus erythematosus. J Immunol. 2009;182:1689–95.PubMed CrossRef 36.Pan X, Yuan X, Zheng Y, Wang W, Shan J, Lin F, et al. Increased CD45RA+ FoxP3(low) regulatory T cells with impaired suppressive function in patients with systemic lupus erythematosus. PLoS One. 2012;7:e34662.PubMed PubMedCentral CrossRef 37.Rodriguez-Perea AL, Montoya CJ, Olek S, Chougnet CA, Velilla PA. Statins increase the frequency of circulating CD4 + FoxP3+ regulatory T cells in healthy individuals. J Immunol Res. 2015;2015:762506.PubMed PubMedCentral CrossRef 38.Zhang D, Wang S, Guan Y, Wang L, Xie W, Li N, et al. Effect of oral atorvastatin on CD4 + CD25+ regulatory T cells, FoxP3 expression, and prognosis in patients with ST-segment elevated myocardial infarction before primary percutaneous coronary intervention. J Cardiovasc Pharmacol. 2011;57:536–41.PubMed CrossRef 39.Mausner-Fainberg K, Luboshits G, Mor A, Maysel-Auslender S, Rubinstein A, Keren G, et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4 + CD25+ T cells. Atherosclerosis. 2008;197:829–39.PubMed CrossRef 40.Meng X, Zhang K, Li J, Dong M, Yang J, An G, et al. Statins induce the accumulation of regulatory T cells in atherosclerotic plaque. Mol Med. 2012;18:598–605.PubMed PubMedCentral CrossRef
作者单位:Luigina Guasti (1) Andrea Maria Maresca (1) (3) Laura Schembri (1) Emanuela Rasini (1) Francesco Dentali (1) Alessandro Squizzato (1) Catherine Klersy (2) Laura Robustelli Test (1) Christian Mongiardi (1) Leonardo Campiotti (1) Walter Ageno (1) Anna Maria Grandi (1) Marco Cosentino (1) Franca Marino (1)
1. Research Center on Dyslipidemia, University of Insubria, Varese, Italy 3. Department of Clinical and Experimental Medicine, University of Insubria, Viale Borri 57, Varese, 21100, Italy 2. Biometry and Clinical Epidemiology, Research Department, Foundation IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy
Background The CD4+ T-lymphocytes and their subtype CD4 + CD25highFoxP3+ regulatory T cells are receiving growing interest as major regulators of atherogenesis. We sought to investigate 1) whether the CD4 + cell subsets were expressed differently in dyslipidemic patients (Pts) and healthy subjects (HS) and 2) whether atorvastatin treatment could be associated in-vivo and in-vitro with cell changes in expression and functional response.